April 1 (Reuters) - Eli Lilly on Wednesday became the second company to gain approval for a weight-loss pill, as the multibillion-dollar market shifts toward more convenient oral therapies.
The global weight-loss drug market is also entering a new phase as generic rivals loom and U.S. prices slip for blockbuster treatments from Eli Lilly and Novo Nordisk.
The fast-changing landscape has prompted Wall Street to rethink long-held forecasts of a $150 billion market within the next decade.
Here are some
companies racing to develop oral obesity drugs in the hopes of making their mark in a lucrative market:
NOVO NORDISK
Novo was the first company to launch a GLP-1 pill for obesity, giving the Danish drugmaker a competitive edge in the fast-evolving obesity treatment market.
The pill was approved by the U.S. Food and Drug Administration in December and is also under review by other regulators, with a UK decision due by year-end.
ELI LILLY
Orforglipron, the company's once-daily oral non-peptide GLP-1 agonist, branded as Foundayo, helped overweight adults without diabetes lose 12.4% of their body weight over 72 weeks at the highest dose in a late-stage trial.
In another study, orforglipron helped maintain weight loss in patients switching from its GLP-1 injection, Zepbound, and rival Novo Nordisk's Wegovy.
STRUCTURE THERAPEUTICS
Structure Therapeutics is developing GSBR-1290, a non-peptide oral GLP-1 agonist. The pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study of 230 people.
Structure plans to start late-stage development of the pill by mid-2026 after a meeting with the FDA in the first half of next year.
MERCK
The company, in partnership with Hansoh Pharma, is preparing to test HS-10535, an oral small-molecule GLP-1 agonist, in early stage trials. The drug is currently undergoing lab studies.
ASTRAZENECA
AstraZeneca and Eccogene are advancing ECC5004, a once-daily GLP-1 receptor agonist pill. Early-stage trial showed a promising weight-loss signal and a favorable safety profile, with mid-stage trials planned under AstraZeneca's lead.
ROCHE
Roche, following its acquisition of Carmot Therapeutics, is working on CT-966, an oral GLP-1 agonist. CT-966 resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patients without diabetes in an early-stage trial last year.
VIKING THERAPEUTICS
The company is developing an oral formulation of VK2735, which targets both GLP-1 and GIP hormones that regulate the body's metabolism.
In a mid-stage study, the experimental weight-loss pill helped patients lose 12.2% of their body weight, missing Wall Street's top-end expectations of 15%.
PFIZER
Pfizer entered the lucrative obesity drug market with its $10 billion acquisition of obesity drug developer Metsera after a fierce bidding war with Novo.
The drugmaker gained access to two oral, long-acting GLP-1 drugs as part of the deal, which are currently being tested in preclinical trials.
Pfizer and Chinese partner Sciwind Biosciences secured approval for their once-weekly weight-loss injection, Xianweiying, in China, adding pressure on approved rivals from Novo, Lilly and Innovent Biologics.
Pfizer was developing danuglipron, initially as a twice-daily oral GLP-1 agonist, but scrapped development after data from a mid-stage trial showed poor tolerability.
Innovent Biologics
China-based Innovent Biologics' oral GLP-1 weight-loss drug, IBI3032, is being tested in early-stage trials in the U.S. and China.
HuaDong Pharmaceutical
China-based HuaDong Pharmaceutical's oral obesity drug candidate, HDM1002, reduced body weight by up to 6.8% in an early-stage study of overweight or obese participants in China.
Ascletis Pharma
China-based Ascletis Pharma's experimental oral GLP-1 drug, ASC30, showed weight-loss of up to 7.7% in a mid-stage study in the U.S.
(Reporting by Bhanvi Satija, Mrinalika Roy, Padmanabhan Ananthan, Siddhi Mahatole, Mariam Sunny and Sneha S K in Bengaluru; Editing by Sriraj Kalluvila)
